Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Baraclude · 1 trial · 1 indication
Cmax is defined as the peak plasma concentration
Tmax is defined as the time of maximum observed plasma concentration, measured in hours
Ctrough is defined as the trough in observed plasma (predose) concentrations
C24 is defined as the observed plasma concentration at 24 hours post-dose
AUC(TAU) is defined as the area under the concentration-time curve in one dosing interval
CLT/F is defined as the apparent total body clearance
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Baraclude | DRUG | Specified dose on specified day |
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. * Participants with chronic hepatitis B (CHB) (excluding participants with a superinfection) who have been confirmed to have CHB. * Participants who are being...
Baraclude is used for the treatment of Hepatitis B Virus infection. It is a small molecule therapeutic being developed in the infectious disease area. The drug is currently in Phase 1 clinical development, with studies conducted to better understand its pharmacokinetic properties in a real world clinical setting.
Baraclude is developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this small molecule drug for Hepatitis B Virus infection, with a completed Phase 1 study in Japan.
Baraclude is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. One Phase 1 study has been completed, which enrolled 6 participants with Hepatitis B Virus in Japan to evaluate the drug's pharmacokinetic properties.
Baraclude has one completed clinical trial registered as NCT03083821, titled "A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting." This Phase 1 study enrolled 6 participants with Hepatitis B Virus in Japan, with a minimum age of 20 years.
Baraclude is a small molecule therapeutic being studied for Hepatitis B Virus infection. The specific molecular target of Baraclude has not been disclosed in the available clinical trial information. The completed Phase 1 study focused on understanding its pharmacokinetic properties in a real world clinical setting.